News
Kawasumi Laboratories, Inc.
Kuraray Medical Inc. (Head Office: Chiyoda-ku, Tokyo; President: Sadaaki Matsuyama) and Kawasumi Laboratories, Inc. (Head Office: Shinagawa-ku, Tokyo; President: Yukihiro Kawano). have announced the reaching of a basic agreement to transfer the business rights for Kuraray Medical's therapeutic apheresis device business to Kawasumi Laboratories on October 1, 2009 Details of the transfer are as follows.
Reference
| President | Sadaaki Matsuyama |
|---|---|
| Established | June 2001 |
| Paid-in capital | ¥300 million (100% owned by Kuraray Co., Ltd.) |
| Head office | 1-1-3, Otemachi, Chiyoda-ku, Tokyo |
| Production facilities | Kurashiki Plant (Okayama Prefecture) |
| Main products | Therapeutic apheresis products, dental adhesives and filling resin |
| Net sales | ¥7 billion (Fiscal year ended March 31, 2009) |
| Employees | Approximately 250 (As of March 31, 2009) |
| President | Yukihiro Kawano |
|---|---|
| Established | June, 1957 |
| Paid-in capital | ¥6.6 billion |
| Head office | 3-28-15, Minami-Oi, Shinagawa-ku, Tokyo |
| Production facilities | Saiki Plant, Yayoi Plant, Mie Plant (Oita Prefecture) |
| Main products | Manufacture and sale, export and import of medical devices and pharmaceuticals |
| Net sales | ¥28.8 billion (Fiscal year ended March 31, 2009, non-consolidated) |
| Employees | Approximately 1,000 (Fiscal year ended March 31, 2009) |
Explanation of Terms
Apheresis Therapy
Apheresis therapy involves the utilization of a device as a therapeutic system to treat the blood of patients in liver failure, a condition that is difficult to treat using only drugs and other medical therapies. Apheresis involves eliminating etiologic agents that are found in blood plasma through extracorporeal circulation. The filtration material used in the apheresis device includes a hollow-fiber membrane derived from synthetic polymer (polysulfone, EVOH, polyacrylonitrile, polyethylene, etc.) an absorbent and nonwoven fabric.
